Fig. 1

Geniposide improves cardiac function of mice suffering from MI/RI. A The chemical structure of geniposide. B The experimental design of our work. To examinate the effect of geniposide on MI/RI, the animals were divided into GEN treatment, I/R + Vehicle, and sham groups. To determine the mechanism of action of geniposide, another set of animals was administered with either Compound C or AICAR immediately at the beginning of reperfusion. The H/R model was launched in NRVMs and H9c2 cells. Compound C and AICAR, si-TXNIP, or si-NLRP3 were adopted to reveal the roles of pyroptosis and the AMPK/TXNIP/NLRP3 signaling on the cardioprotective effect of geniposide. C Representative echocardiograms in M-mode records of left ventricular (LV) and analysis of LV ejection fraction (LVEF), fractional shortening (LVFS), LV end-diastole diameter (LVEDd), and LV end-systolic diameter (LVESd) (n = 6). D–F The activity of myocardial enzymes LDH, CK-MB, and CK levels in serum of mice (n = 6). G Representative TTC–Evans Blue stained sections of hearts and quantitative data of the LV infarct size. Infarct size (%) was expressed as the percentage of infarct area relative to the total left ventricular area. the nonischemic section shown in blue area, red represent risk area, and the infarct region is stained white (n = 6). H Representative H&E staining of the left ventricular area. Scale bar = 50 μm (n = 5). The data for each group were shown as the mean ± SD; ^#p < 0.05, ^##p < 0.01 vs. Sham group; *p < 0.05, **p < 0.01 vs. I/R + Vehicle group